In the PDX model COG-N-496x28, a TP53 mutant model developed at diagnosis, WEHI-7326 (20 mg/kg i.v. twice weekly) slowed tumor growth and extended median survival from 15 days to 25 days (Fig. 7a, b). Here, TP53 is linked to neoplasm.